Abstract
The evolutionary changes in immune profiles of triple negative breast cancer (TNBC) are not well understood, although it is known that immune checkpoint inhibitors have diminished activity in heavily pre-treated TNBC patients. This study was designed to characterize immune profile changes of longitudinal tumor specimens by studying immune subsets of tumor infiltrating lymphocytes (TILs) in paired primary and metastatic TNBC in a cohort of "poor outcome" (relapsed within 5 years) patients. Immune profiles of TNBCs in a cohort of "good outcome" (no relapse within 5 years) patients were also analyzed. Immune subsets were characterized for CD4, CD8, FOXP3, CD20, CD33, and PD1 using immuno-fluorescence staining in stroma, tumor, and combined stroma and tumor tissue. TIL subsets in "good outcome" versus "poor outcome" patients were also analyzed. Compared with primary, metastatic TNBCs had significantly lower TILs by hematoxylin and eosin (H&E) staining. Stromal TILs (sTILs), but not tumoral TILs (tTILs) had significantly reduced cytotoxic CD8+ T cells (CTLs), PD1+ CTLs, and total PD1+ TILs in metastatic compared with matched primary TNBCs. Higher PD1+ CTLs, PD1+CD4+ helper T cells (PD1+TCONV) and all PD1+ T cells in sTILs, tTILs and...Continue Reading
References
Oct 2, 2008·Cancer Immunology, Immunotherapy : CII·Yu LiuRongcun Yang
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Dec 14, 2011·Breast Cancer Research : BCR·Nathan R WestPeter H Watson
Feb 26, 2013·Cancer Research·Intissar AkalaySalem Chouaib
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LoiC Sotiriou
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Sep 26, 2015·Oncoimmunology·Sylvia AdamsSunil S Badve
Nov 21, 2015·Histopathology·Rhiannon K BeckersSandra A O'Toole
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G PruneriG Viale
Mar 12, 2016·Annals of Surgical Oncology·Shannon K SwisherElizabeth A Mittendorf
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jul 5, 2016·Nature Medicine·Hong JiangDavid G DeNardo
Apr 2, 2017·The Breast : Official Journal of the European Society of Mastology·Giancarlo PruneriCarsten Denkert
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G PruneriG Viale
Dec 14, 2017·The Lancet Oncology·Carsten DenkertSibylle Loibl
Jan 4, 2018·Oncoimmunology·Sylvain Simon, Nathalie Labarriere
Feb 22, 2018·Oncotarget·Gero BrockhoffAnja Kathrin Wege
Mar 17, 2018·Frontiers in Immunology·Linda ZianiJerome Thiery
Mar 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hope S RugoAntoinette R Tan
Mar 30, 2018·JAMA Oncology·Heather HampelUNKNOWN Ohio Colorectal Cancer Prevention Initiative Study Group
Aug 30, 2018·NPJ Breast Cancer·Kim R M BlenmanPeter P Lee
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Citations
Jun 4, 2020·Cancers·Jin Sun LeeYuan Yuan
Nov 27, 2020·Frontiers in Molecular Biosciences·Qiang JuYan-Jie Zhao
May 1, 2021·Journal of Clinical Medicine·Giovanni CentonzeMassimo Milione
May 1, 2021·Genes·Felicitas MungenastRupert C Ecker
Apr 25, 2021·The Oncologist·Wencheng ZhangQingsong Pang
Jun 3, 2021·Cancers·Richard J BeckJoost B Beltman
Jun 3, 2021·Cancers·Barbora KvokačkováKarel Souček
Jul 3, 2021·Cancers·Jeppe ThagaardEva Balslev
Jul 25, 2021·Cancers·Debaditya ChakrabortyGabriel Lopez-Berestein
Jul 22, 2021·Journal of the National Cancer Institute·Sunil S BadveGiuseppe Viale
Sep 7, 2021·Breast Cancer Research and Treatment·Peter SavasSherene Loi